2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibration
2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/coc.0000000000000849.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRCC brain metastasesBrain metastasesRenal cell carcinomaStereotactic radiosurgeryOverall survivalUse of ICIsCentral nervous system toxicityRenal cell carcinoma patientsImpact of immunotherapyLocal control outcomesMedian overall survivalCell carcinoma patientsKaplan-Meier curvesNervous system toxicityBetter median OSLog-rank testMann-Whitney U testMargin doseMedian OSNonimmunotherapy groupSRS doseCheckpoint inhibitorsImmunotherapy groupCarcinoma patients
2020
Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyEvaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology 2020, 6: 1028-1037. PMID: 32496550, PMCID: PMC7273318, DOI: 10.1001/jamaoncol.2020.1271.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyProgression-free survivalSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesCNS progression-free survivalLung cancer brain metastasesPropensity score-matched analysisMedian overall survivalCancer brain metastasesBrain metastasesOverall survivalStereotactic radiosurgeryCentral nervous system (CNS) progression-free survivalMedian CNS progression-free survivalSRS outcomesCentral nervous system progressionSmall cell lung cancerLimited brain metastasesMulticenter cohort studyDisease control statusCell lung cancerSingle-arm trialStandard of careLeptomeningeal progressionWBRT cohortProceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original Research
2019
Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Beckta J, Nosrati J, Yu J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology Seminars And Original Investigations 2019, 37: 619-627. PMID: 30738746, DOI: 10.1016/j.urolonc.2019.01.015.Peer-Reviewed Original ResearchConceptsModerate hypofractionationRadiation therapyStereotactic body radiation therapyProstate cancer radiation therapyTreatment of prostate cancerCancer radiation therapyReduced duration of treatmentDuration of treatmentStandard of careCurative intentProstate cancerHigh dosesHypofractionationReduced durationDaily sessionsFractionation schemeTherapyEffective alternativeTreatmentProstatePatientsCancerDoseMonthsCare
2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Mahal B, Chen Y, Sethi R, Padilla O, Yang D, Chavez J, Muralidhar V, Hu J, Feng F, Hoffman K, Martin N, Spratt D, Yu J, Orio P, Nguyen P. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer 2017, 124: 1141-1149. PMID: 29231964, DOI: 10.1002/cncr.31190.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyProstate stereotactic body radiotherapyNational Cancer Data BaseLocalized prostate cancerShort-term efficacyProstate cancerTreated with definitive external beam radiotherapyDefinitive external beam radiotherapyDefinitive stereotactic body radiotherapyLong-term clinical implicationsFavorable disease characteristicsExternal beam radiotherapyAssociated with increased adjusted oddsMultivariate logistic regressionAcademic treatment centerAffluent zip codesBeam radiotherapyTreatment optionsDisease characteristicsRadiotherapyAdjusted oddsTreatment decisionsWhite raceYounger ageJoinpoint regression
2016
Emerging Technologies and Techniques in Radiation Therapy
Magnuson W, Mahal A, Yu J. Emerging Technologies and Techniques in Radiation Therapy. Seminars In Radiation Oncology 2016, 27: 34-42. PMID: 27986210, DOI: 10.1016/j.semradonc.2016.08.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyHigh-dose-rateProton beam radiationRadiation therapyProstate cancerHigh-dose-rate (HDR) brachytherapyHigh-risk prostate cancer patientsHigh-risk prostate cancerTreatment of prostate cancerPartial gland treatmentProstate-directed therapyRegional radiation therapyLow-risk diseaseBeam radiationProstate cancer patientsDeliver radiationImprove cancer controlHigh-intensity focused ultrasoundFocal therapyTherapeutic modalitiesRadiation treatmentCancer patientsCancer controlTherapyReduced toxicity
2014
Stereotactic body radiation therapy: Let’s not give up on progress
Yu J, Sandler H. Stereotactic body radiation therapy: Let’s not give up on progress. Practical Radiation Oncology 2014, 5: 193-196. PMID: 25413388, DOI: 10.1016/j.prro.2014.09.001.Peer-Reviewed Original ResearchDecision Analysis of Stereotactic Radiation Surgery Versus Stereotactic Radiation Surgery and Whole-Brain Radiation Therapy for 1 to 3 Brain Metastases
Lester-Coll N, Dosoretz A, Yu J. Decision Analysis of Stereotactic Radiation Surgery Versus Stereotactic Radiation Surgery and Whole-Brain Radiation Therapy for 1 to 3 Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2014, 89: 563-568. PMID: 24751412, DOI: 10.1016/j.ijrobp.2014.03.001.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyStereotactic radiation surgeryQuality-adjusted life monthsQuality-adjusted life expectancyAdjuvant whole-brain radiation therapyBrain metastasesRadiation therapyRadiation surgeryPerformance statusOmission of whole-brain radiation therapyCompare quality-adjusted life expectancySalvage whole brain radiation therapySurveillance magnetic resonance imagingSide effectsQuality of lifeMarkov decision analysis modelControl intracranial diseaseIntracranial tumor controlPoor performance statusCohort of patientsNeurocognitive side effectsOne-way sensitivity analysesKarnofsky performance statusIntracranial progressionIntracranial relapse
2012
Radiosurgical Dose Selection for Brain Metastasis
Yu J, Schulder M, Knisely J. Radiosurgical Dose Selection for Brain Metastasis. Progress In Neurological Surgery 2012, 25: 139-147. PMID: 22236675, DOI: 10.1159/000331187.Peer-Reviewed Original ResearchConceptsDose-escalation trialRadiosurgical doseDose selectionVolume of normal tissueRadiosurgery doseRadiation therapyRadiosurgical treatmentSteep dose gradientsRadiosurgical treatment of brain metastasesRadiation Therapy Oncology GroupTreatment of brain metastasesSingle-fraction dosesBrain radiation necrosisRadiosurgical treatment volumeBrain radiation therapyFractionated radiation therapyDose gradientDose deliveryNormal brain tissueAdjacent normal brain tissuePrimary radiosurgeryBrain metastasesRadiation necrosisOncology GroupTreatment volume